Search Results
Sep 24, 2025, 16:18 ET INTERNATIONALE GESELLSCHAFT FÜR HAARWIEDERHERSTELLUNGSCHIRURGIE VERANSTALTET 33. WELTKONGRESS, 23. bis 25. OKTOBER 2025, IN BERLIN, DEUTSCHLAND, MIT AUSVERKAUFTEM LIVE-CHIRURGIE-WORKSHOP am 26
im Jahr 2024 jünger als die Allgemeinbevölkerung: 95 % der Patienten, die eine Haarwiederherstellung vornehmen lassen, sind zwischen 20 und 35 Jahre alt. Die dreitägige Konferenz und der ausverkaufte Live-Chirurgie-Workshop werden voraussichtlich mehr als 800 Ärzte und chirurgische Assistenten
More news about: International Society of Hair Restoration Surgery
Sep 24, 2025, 09:40 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities
More news about: Faruqi & Faruqi, LLP
Sep 24, 2025, 09:00 ET MEDIA COMPANY RAPTIVE LAUNCHES 'CTRL ALT ASK' PODCAST, A CREATOR ADVICE SHOW
'Ctrl Alt Ask' builds on Raptive's longstanding commitment to empower creators and publishers on the open web.Hosted by Stephanie Woodin, Raptive's senior director of publicity and former manager of original series publicity at Netflix, "Ctrl Alt Ask" is
More news about: Raptive
Sep 23, 2025, 12:00 ET SMIRNOFF UND TROYE SIVAN VERÖFFENTLICHEN NEUES GESCHÄFTSUPDATE AUS DEM „VIBES HQ" UND STARTEN DIE „BRIEFCASE DROP"-SCHNITZELJAGD FÜR FANS
demnächst über @smirnoff auf Instagram BRIEFCASE DROP T&CS **Die Crew besteht aus 3 Personen, die alle über 21 Jahre alt sein müssen. †Um Hinweise zu sehen, ist ein Instagram-Account erforderlich. KEIN KAUF ERFORDERLICH. Wird nur im Raum
More news about: Smirnoff
Sep 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
2025 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or
More news about: Pomerantz LLP
Sep 23, 2025, 09:03 ET Flamel.ai Launches New Suite of Product Capabilities Enabling Franchises to Grow Local Revenue
dashboard.Bulk Scheduling with AI‑Generated Captions. Franchise teams can generate a month's worth of social posts, captions, alt‑text and hashtags in seconds, freeing marketers and franchisees from time‑consuming manual work that can now be reinvested in strategy, community engagement
More news about: Flamel.ai
Sep 22, 2025, 21:37 ET ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of
More news about: THE ROSEN LAW FIRM, P. A.
Sep 22, 2025, 08:45 ET The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
More news about: The Gross Law Firm
Sep 22, 2025, 08:11 ET INVESTOR ALERT: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between
More news about: Berger Montague
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
INDIGO Study was consistent with the results of the Phase 1 trials. Overall, the most common adverse reactions, including laboratory abnormalities, were ALT increased, AST increased, GGT increased, fatigue and diarrhea. About Glioma5Gliomas are tumors that
More news about: Servier Pharmaceuticals
Sep 22, 2025, 07:00 ET Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 52 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence
More news about: Insmed Incorporated
Sep 22, 2025, 03:39 ET ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by
More news about: The Schall Law Firm
Sep 20, 2025, 23:16 ET Huawei, Endüstriyel Zeka için Üç Aşamalı "ACT" Yolunu ve Dokuz Ana Çözümü Tanıttı
paylaştı. İlk olarak Huawei, bankacılık sektörü için sistematik mühendislik yeteneklerini bankacılık iş akışlarına entegre eden dinamik bir ana-alt acente mimarisi geliştirdi. Huawei, müşterilerinin etkileşimler, işlemler ve risk kontrolü gibi bir dizi senaryoda bu mimariyi kullanarak yapay zekâ
More news about: HUAWEI
Sep 19, 2025, 19:43 ET Neue Alchemy Launches AU79 Records in Under 24 Hours
halls, and the blurry in-between. They first played together in Modern Day Arcade, part of Florida's early 2000s alt/punk scene. Steinfeld would go on to anchor Daeava, a melodic hardcore outfit that earned its place sharing stages with Misery Signals and 7 Angels 7
More news about: Neue Alchemy
Sep 19, 2025, 08:45 ET October 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT
19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Sep 19, 2025, 08:30 ET TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations
More news about: Johnson & Johnson
Sep 19, 2025, 05:28 ET DarwinCell Showcases novel MSC-based drug ALT001 at the 150th American Neurological Association Annual Meeting
safety and the efficacy of ALT001 on ALS patients. After 2-weeks of administration of ALT001, most patients reported positive outcomes, as demonstrated by elevated performance, ALSFRS-R and modified Norris scores. "We are greatly honored to share the latest data on ALT001 at this global academic
More news about: Darwincell Biotech
Sep 18, 2025, 19:00 ET DACLab Launches Out of Stealth with Most Cost-Efficient DAC System named "Kelvin" Aimed at Large E-fuels and CO2 Sequestration Markets
emerged from stealth with a $3 million seed round and the launch of its first commercial product at their flagship "Ctrl+Alt+DAC" event. The round was led by Peter Relan, founder of YouWeb Incubator and early investor in Discord, with participation
More news about: DACLab
Sep 18, 2025, 18:40 ET Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities
More news about: Faruqi & Faruqi, LLP
Sep 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or
More news about: Pomerantz LLP
Sep 18, 2025, 09:48 ET Mleiha-Nationalpark: Sharjahs erstes Öko-Tourismusjuwel im Herzen der VAE
die alle für das Ökosystem des Parks lebenswichtig sind. Neben der reichen Tierwelt bieten Fossilien, die zwischen 93 und 65 Millionen Jahre alt sind, einen weiteren Einblick in die reiche Geschichte von Mleiha, darunter erhaltene Korallen, Meeresfossilien und Kalksteinfelsen. Mleiha wurde
More news about: Mleiha National Park
Sep 18, 2025, 09:00 ET Centari Raises $14 Million to Pioneer Deal Intelligence in the Enterprise AI Market
million in funding, including an oversubscribed Series A. The round was led by Sentinel Global with participation from GTMfund, South Park Commons, Alt Capital, RiverPark Ventures, Recall Capital, and strategic partners in the fintech and legal industries.
More news about: Centari
Sep 18, 2025, 08:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT
Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
More news about: The Gross Law Firm
Sep 18, 2025, 05:41 ET ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by
More news about: The Schall Law Firm
Sep 17, 2025, 03:40 ET Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)
Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its subsidiary, Alteogen Biologics. EYLUXVI® is Alteogen's second
More news about: Alteogen Inc.